Cautionary Note Regarding Forward-Looking Statements. As used in this report, the terms Aptose, Aptose Biosciences, the Company, "the "Corporation," we, us, our and similar references refer to Aptose Biosciences Inc. (formerly known as Lorus Therapeutics Inc.) and our consolidated subsidiaries, and the term Common Shares refers to our common shares, no par value. Aptose had historically qualified as a foreign private issuer for purposes of reporting under the Exchange Act, and filing registratio...
Q2 FY2026 — expected 2026-09-21
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001193125-26-135012 | EDGAR | 80K words |
| 2025-03-28 | 2024-12-31 | 0000950170-25-046366 | EDGAR | — |
| 2024-03-26 | 2023-12-31 | 0000950170-24-036537 | EDGAR | — |
| 2023-03-24 | 2022-12-31 | 0000950170-23-009560 | EDGAR | — |
| 2022-03-22 | 2021-12-31 | 0001171843-22-002048 | EDGAR | — |
| 2021-03-23 | 2020-12-31 | 0001171843-21-002006 | EDGAR | — |
| 2020-03-10 | 2019-12-31 | 0001171843-20-001617 | EDGAR | — |
| 2019-03-12 | 2018-12-31 | 0001171843-19-001661 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001193125-25-280433 | EDGAR | 29K words |
| 2025-08-13 | 2025-06-30 | 0000950170-25-108110 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066391 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-124343 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-094205 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059768 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062207 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041441 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0000950170-23-018923 | EDGAR | — |
| 2022-11-01 | 2022-09-30 | 0001171843-22-006964 | EDGAR | — |
| 2022-08-02 | 2022-06-30 | 0001171843-22-005260 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0001171843-22-003463 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-31 | 0001171843-26-002103 | EDGAR | 3K words |
| 2026-03-31 | 0001193125-26-134870 | EDGAR | — |
| 2026-03-23 | 0001193125-26-119951 | EDGAR | — |
| 2026-03-23 | 0001171843-26-001837 | EDGAR | — |
| 2026-03-19 | 0001171843-26-001777 | EDGAR | — |
| 2026-02-24 | 0001193125-26-064847 | EDGAR | — |
| 2025-12-19 | 0001171843-25-008045 | EDGAR | — |
| 2025-12-08 | 0001171843-25-007795 | EDGAR | — |
| 2025-11-25 | 0001193125-25-294108 | EDGAR | — |
| 2025-11-19 | 0001171843-25-007415 | EDGAR | — |
681 total filings indexed. 651 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000882361 |
| Ticker | APTOF |
| Exchange | OTC |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | A6 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report